Dr Tim O'Brien discusses tough medical experiences, while Dr Carlo Bravi argues why young urologists should learn open surgery, despite robotic surgery.
A study revealed that osteoarthritis is associated with a wide variety of diseases previously thought to be unrelated, such as anaemia and thromboembolic disease.
Prof. Fanos, addresses how COVID-19, AI, Big Data and the future of medicine may impact our relation with the microbiome.
Musculoskeletal disease patients manage moderate-to-vigorous physical training, but fail the recommended daily steps.
“À Chacun Son Everest!” organises trips that are of great inspiration for the children and women in remission joining; and for the physicians travelling with them.
Post-surgery hospital stay was much shorter for bladder cancer patients after full robotic radical cystectomy over those treated with open surgery.
According to a Spanish study, patients with rheumatoid arthritis and psoriatic arthritis have a markedly deteriorated sexual life compared with a healthy population.
Sarilumab demonstrated positive results in a phase 3 trial for PMR patients. More participants reached sustained remission and reduced flare risk.
The IL-17A/IL-17F blocker bimekizumab showed marked superiority in the primary and all ranked secondary endpoints of the phase 3 BE OPTIMAL trial as a PsA therapy.
A register study explored worldwide data on MACEs and venous thromboembolism associated with JAK inhibitors compared to anti-TNF agents in RA.
Prof. Dr. Reinhard Renneberg uses his own DNA as an example to show which migratory routes his earliest ancestors took.
A post-hoc trial analysis revealed nintedanib treatment benefit in patients with 4 characteristics associated with a fast decline in lung function.
A large register study in Denmark detected a substantially higher mortality risk for patients with rheumatoid arthritis (RA) who had comorbid depression.
Deucravacitinib showed convincing results as a treatment for patients with active systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial.
Cohort study data detected factors linked to a risk amplification for dementia development in patients with rheumatoid arthritis.
During the double-blind period of a withdrawal trial, baricitinib demonstrated predominance over placebo in the prevention of disease flares.
Once-daily therapy with upadacitinib led to an ASAS40 response in 45% of patients with active nr-axSpA at week 14 in the SELECT-AXIS-2 trial.
esanum talks with Prof. Brunetti about AI in medicine, its ethical implications and physicians' approach to this tech revolution.
Trial results show equal DA-EPOCH-R efficacy to CODOX-M/R-IVAX as first-line treatment in patients, but less toxicity.
New technologies have transformed haematology. Gene-editing and molecular agents become available to patients within shorter timeframes.